Expert Interview
Discussing the potential of Regeneron's otoferlin gene therapy, currently being investigated in the Phase 1/2 CHORD trial for patients with genetic hearing loss
Ticker(s): REGN, AKUS, LLYInstitution: University of Washington
- Director of the UW's Bloedel Hearing Research Center and a UW professor of Head and Neck Surgery and Bioengineering
- Manages 100+ patients for genetic hearing loss
- Clinical interests include tumors of the lateral skull base and nerve disorders
Describe your background and practice setting
Added By: ben_adminHow many patients with genetic hearing loss do you currently manage?
Added By: ben_adminWhat are your thoughts on the potential of otoferlin?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
